Souhaitez-vous accéder aux communiqués récents ?

SONATA-HCM anticipated to be fully enrolled mid-2026  Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851...

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12  ...

Digital Realty Expands Talent Development Opportunities for Operations Workforce Through Partnership with DCD Academy

Washington, DC, May 05, 2026 (GLOBE NEWSWIRE) -- Today (May 5, 2026), on World Asthma Day, the Asthma and Allergy Foundation of America (AAFA), along with the American Academy of Allergy, Asthma,...

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular...

What 2026 buyers should verify: Halo Care Skin Tag Remover claims, ingredients, pricing, refund terms, and dermatologist guidance.

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...

Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...